Sagimet BiosciencesSTU:0O2 +2.15%10 Price-to-Tangible-Book is 2.44 as of Jul. 03, 2026, which is 79% above its 10-year median of 1.36. GuruFocus rates STU:0O2 with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 1,150 Biotechnology companies, Sagimet Biosciences ranks better than 62.09% on this metric.
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Sagimet Biosciences Price-to-Tangible-Book Related Terms
Sagimet Biosciences Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for Sagimet Biosciences's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:0O2 vs EDIT, AUTL, FBRX: Price-to-Tangible-Book Comparison
For the Biotechnology subindustry, Sagimet Biosciences's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sagimet Biosciences Price-to-Tangible-Book vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sagimet Biosciences's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Sagimet Biosciences's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Sagimet Biosciences (STU:0O2) has a Price-to-Tangible-Book of 2.44 as of Jul. 03, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Sagimet Biosciences and its competitors. This is 79% above median its historical median of 1.36. Over the past decade, Sagimet Biosciences' Price-to-Tangible-Book has ranged from 0.52 to 2.43. According to the industry distribution chart, Sagimet Biosciences ranks #436 out of 1150 companies in the Biotechnology industry, placing it in the top 37.9%.
Is Sagimet Biosciences' Price-to-Tangible-Book too high?
Sagimet Biosciences' current Price-to-Tangible-Book of 2.44 is 79% above median its 10-year median of 1.36. Over the past 10 years, this metric has ranged from a low of 0.52 to a high of 2.43. The Biotechnology industry median Price-to-Tangible-Book is 3.25. Sagimet Biosciences' value of 2.44 is 24.9% below this industry median. Based on the distribution chart, Sagimet Biosciences ranks #436 out of 1150 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Sagimet Biosciences has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Sagimet Biosciences' Price-to-Tangible-Book compare to EDIT and AUTL?
According to the Biotechnology industry distribution chart, Sagimet Biosciences ranks #436 out of 1150 companies for Price-to-Tangible-Book. This puts Sagimet Biosciences in the upper half of its industry. The industry median Price-to-Tangible-Book is 3.25. Sagimet Biosciences' value of 2.44 is 24.9% below this benchmark. Historically, Sagimet Biosciences' own Price-to-Tangible-Book has ranged from 0.52 to 2.43 over the past decade. While the company's 10-year median is 1.36 vs. the industry median of 3.25, Sagimet Biosciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Biotechnology company?
The median Price-to-Tangible-Book among Biotechnology companies is 3.25, based on 1,150 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sagimet Biosciences's current Price-to-Tangible-Book of 2.44 is 24.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Sagimet Biosciences and its competitors. For the Biotechnology industry, the median Price-to-Tangible-Book is 3.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sagimet Biosciences's current Price-to-Tangible-Book is 2.44, which is 79% above median its own 10-year median of 1.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sagimet Biosciences stock overvalued right now?
Sagimet Biosciences (STU:0O2) has a current Price-to-Tangible-Book of 2.44. The current Price-to-Tangible-Book is 2.44, which is 79% above median its 10-year median of 1.36 and 24.9% below the Biotechnology industry median of 3.25. Sagimet Biosciences' overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Sagimet Biosciences (STU:0O2), the current Price-to-Tangible-Book is 2.44 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
10GF Score
Get the complete analysis for STU:0O2
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:0O2 has been successfully added to your 
